Oseltamivir (Tamiflu): Comprehensive Dosing and Clinical Use Guidelines

Adult Treatment and Prophylaxis (≥13 years)

For otherwise healthy adults and adolescents ≥13 years, prescribe oseltamivir 75 mg orally twice daily for 5 days to treat acute influenza, and 75 mg once daily for 10 days for post-exposure prophylaxis. 1

Treatment Regimen

Standard dose: 75 mg orally twice daily for 5 days 1, 2
Timing: Initiate within 48 hours of symptom onset for maximal benefit; starting within 12–24 hours provides an additional 1–3 days of symptom reduction compared to initiation at 48 hours 1, 3
Complete the full course: Continue all 5 days even if symptoms resolve earlier to ensure adequate viral suppression and prevent resistance 1

Prophylaxis Regimen

Standard dose: 75 mg orally once daily for 10 days after household exposure 1, 4
Community outbreak prophylaxis: May be extended up to 6 weeks during widespread influenza activity 4
Timing: Initiate within 48 hours of exposure to an infected individual 4

Administration

Take with food to significantly reduce nausea and vomiting, which occur in approximately 10% of patients 1, 3
Available as 30 mg, 45 mg, and 75 mg capsules 1

Pediatric Weight-Based Dosing (≥12 months)

Children ≥12 months require weight-based dosing using the oral suspension (6 mg/mL) or capsules, with doses ranging from 30–75 mg depending on body weight. 1

Treatment (Twice Daily for 5 Days)

Body Weight	Dose per Administration	Oral Suspension Volume (6 mg/mL)
≤15 kg (≤33 lb)	30 mg	5 mL
>15–23 kg (>33–51 lb)	45 mg	7.5 mL
>23–40 kg (>51–88 lb)	60 mg	10 mL
>40 kg (>88 lb)	75 mg	12.5 mL

1, 2

Prophylaxis (Once Daily for 10 Days)

Use the same weight-based dose as treatment but administered once daily instead of twice daily 1, 4

Critical Dosing Pitfalls to Avoid

Do not round up inappropriately: A 33 kg child receives 60 mg, not 75 mg 1
Do not use household spoons: Always employ a calibrated oral syringe for accurate measurement 1
Do not confuse treatment (twice daily) with prophylaxis (once daily) dosing 4

Infant Dosing (<12 months)

Infants require age-based or weight-based mg/kg dosing calculated precisely and measured with a calibrated oral syringe; do not apply the categorical weight-based dosing used for older children. 1

Term Infants (≥37 weeks gestation)

9–11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 2
0–8 months: 3.0 mg/kg per dose twice daily for 5 days 1, 2
Example: A 4.5 kg, 6-month-old term infant receives 13.5 mg (3.0 mg/kg × 4.5 kg) = 2.25 mL of 6 mg/mL suspension twice daily 1

Prophylaxis in Infants

3–11 months: 3.0 mg/kg once daily for 10 days 1, 4
<3 months: Prophylaxis is not recommended unless the clinical situation is judged critical due to limited safety data 1, 4

Preterm Infants (Post-menstrual Age-Based)

Preterm infants require substantially lower doses based on post-menstrual age (PMA = gestational age + chronologic age) to avoid toxic drug accumulation from immature renal function. 1

Post-menstrual Age	Dose (mg/kg) Twice Daily
<38 weeks PMA	1.0 mg/kg
38–40 weeks PMA	1.5 mg/kg
>40 weeks PMA	3.0 mg/kg

Example: A 4.5 kg preterm infant at 36 weeks PMA receives 4.5 mg (1.0 mg/kg × 4.5 kg) = 0.75 mL of 6 mg/mL suspension twice daily 1
Critical warning: Using term-infant dosing for preterm infants can cause toxicity; PMA-based dosing is mandatory 1
Extremely preterm infants (<28 weeks PMA): Consult a pediatric infectious disease specialist before initiating therapy 1

FDA Approval and Off-Label Use

FDA-approved for treatment starting at 2 weeks of age 1
Clinicians may initiate therapy from birth (including preterm infants) when anticipated benefit outweighs risk 1

Renal Impairment Dose Adjustments

Dose reduction is mandatory for patients with creatinine clearance <60 mL/min to prevent drug accumulation and toxicity; failure to adjust can lead to serious adverse events. 1, 5

Treatment Adjustments (CrCl 10–30 mL/min)

Standard adjustment: 75 mg once daily (instead of twice daily) for 5 days 6, 1
Alternative low-dose regimen: 30 mg once daily for 5 days 1

Prophylaxis Adjustments (CrCl 10–30 mL/min)

Option 1: 30 mg once daily for 10 days 6, 4
Option 2: 75 mg every other day for 10 days (total of 5 doses) 6, 4

Pediatric Renal Adjustments

For children with CrCl 10–30 mL/min, administer the weight-based dose once daily instead of twice daily for treatment 2

Important Considerations

Age is not the determining factor in elderly patients; renal function (not age) dictates dose reduction 1
Hemodialysis contributes minimally to oseltamivir clearance 1

Formulations and Compounding

Available Formulations

Capsules: 30 mg, 45 mg, 75 mg 1
Oral suspension: 6 mg/mL after reconstitution 1

Compounding When Commercial Suspension Unavailable

Capsules may be opened and contents mixed with a sweetened liquid (e.g., simple syrup or Ora-Sweet SF) to achieve 6 mg/mL concentration 6, 1
Pharmacies can compound suspension according to package insert instructions 6, 1

Contraindications and Special Populations

No Absolute Contraindications

Egg allergy does not contraindicate oseltamivir use 4
Pregnancy and breastfeeding are not contraindications; pregnant women receive the standard adult regimen (75 mg twice daily for 5 days) 2

High-Risk Populations Requiring Prompt Treatment

Initiate oseltamivir in high-risk patients even if presentation occurs >48 hours after symptom onset. 2

High-risk groups include: 2

Children <2 years old
Adults ≥65 years old
Pregnant and postpartum women (up to 2 weeks postpartum)
Individuals with chronic cardiac or respiratory disease (including asthma)
Patients with diabetes, immunodeficiency, or other chronic conditions
Residents of long-term care facilities

Common Adverse Effects and Management

Gastrointestinal Effects

Nausea: Occurs in approximately 10% of adults 1, 7
Vomiting: Occurs in approximately 9% of adults and 14% of children 1, 7
Management: Taking oseltamivir with food significantly reduces severity; symptoms are mild, transient, and resolve within 1–2 days 1, 3
Discontinuation: Only approximately 1% of patients discontinue due to gastrointestinal side effects 1

Neuropsychiatric Events

Rare cases of delirium, hallucinations, and abnormal behavior reported primarily in pediatric and adolescent patients in post-marketing surveillance 1
Important: Influenza infection itself is strongly associated with neurologic and behavioral symptoms even without antiviral therapy 1
Vivid dreams are not a recognized adverse effect of oseltamivir in major guidelines or FDA labeling 1

Other Adverse Effects

Headache: Increased risk in prophylaxis studies (3.15% risk difference; NNTH 32) 7
Psychiatric events: Increased risk in prophylaxis studies (1.06% risk difference; NNTH 94) with dose-response effect observed 7
Renal events: Slight increase in prophylaxis studies (0.67% risk difference) 7

Alternative Antiviral: Zanamivir

For patients who cannot tolerate oseltamivir or have contraindications, zanamivir 10 mg (two 5-mg inhalations) twice daily for treatment or once daily for prophylaxis is an alternative for patients ≥5 years old. 6, 4

Zanamivir Contraindications

Contraindicated in patients with underlying airway disease (asthma, COPD) due to risk of bronchospasm 6, 4
Administered via proprietary "Diskhaler" device; not a nebulized aerosol 6

Drug Interactions

Live Attenuated Influenza Vaccine (LAIV)

Avoid LAIV within 48 hours before starting oseltamivir 1
Do not use oseltamivir for 14 days after LAIV vaccination to avoid interference with vaccine efficacy 1, 4

Clinical Efficacy and Evidence

Treatment Benefits

Reduces illness duration by approximately 1–1.5 days (24–36 hours) compared to placebo 1, 8
Reduces need for subsequent antibiotic therapy 1
Reduces investigator-mediated unverified pneumonia by 1.00% (NNTB 100) in adults, though effect not significant in trials using detailed diagnostic criteria 7

Prophylaxis Benefits

Reduces symptomatic influenza by 55% in individuals (NNTB 33) 7
Reduces household transmission by 13.6% (NNTB 7) based on one study 7
Provides >70% protection during seasonal prophylaxis in unvaccinated adults 8

Timing and Maximal Benefit

Treatment within 12 hours of symptom onset reduces illness duration by an additional 74.6 hours compared to initiation at 48 hours 3
Treatment within 24 hours reduces illness duration by an additional 53.9 hours compared to initiation at 48 hours 3

Resistance and Viral Susceptibility

Influenza B strains are almost universally susceptible to oseltamivir 2
Resistance is rare and mutants show reduced transmissibility and pathogenicity 3
Completing the full 5-day course helps prevent resistance development 1

Special Dosing Considerations

Large Body Mass

Current standard dosing may be inadequate for patients with large body mass; first dose should be proportionately larger 5
Consider therapeutic drug monitoring in obese patients to optimize dosing 5

Mild to Moderate Renal Impairment

Standard dose reductions focus on steady-state concentrations but may delay achievement of therapeutic concentrations early in infection 5
First dose should be 75 mg (standard) with subsequent doses reduced based on creatinine clearance 5

Help us tailor your experience